Targeted delivery of Botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions

Details for Australian Patent Application No. 2005326660 (hide)

Owner Allergan, Inc.

Inventors Blumenfeld, Andrew M.

Agent Davies Collison Cave

Pub. Number AU-B-2005326660

PCT Pub. Number WO2006/083455

Priority 60/593,641 01.02.05 US

Filing date 29 December 2005

Wipo publication date 10 August 2006

Acceptance publication date 19 July 2012

International Classifications

A61K 38/16 Medicinal preparations containing peptides - Peptides having more than 20 amino acids

A61K 35/74 Medicinal preparations containing material or reaction products thereof with undetermined constitution

Event Publications

23 August 2007 PCT application entered the National Phase

  PCT publication WO2006/083455 Priority application(s): WO2006/083455

30 July 2009 Assignment before Grant

  KBBY, LLC The application has been assigned to Allergan, Inc. 2006

19 July 2012 Application Accepted

  Published as AU-B-2005326660

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005326675-Method to prepare bis(halophthalimides)

2005326659-Multicyclic bis-amide MMP inhibitors